Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

New questions surround Oklahoma’s billion-dollar rural health initiative. We're tracking how that money will be spent over ...

ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...

ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

Dr. Lynetta Payne, a urologist at Raleigh General Hospital, has reached the milestone of 200 successful Aquablation surgeries. Aquablation is a minimally-invasive ...

Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage bladder cancer.

Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company’s ...

Oncology Media Relations   Oncology_media_relations@its.jnj.com     Investor contact: Jess Margevich investor-relations@its.jnj.com ...

Drs Uzzo, Chung, and Croll of Fox Chase Cancer Center at Temple University Health discuss top presentations from the ASCO Genitourinary Cancers Symposium 2026. The American Society of Clinical ...